urothelial carcinoma

You have access
Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study
NOBUKI FURUBAYASHI, AKINORI MINATO, TOSHIHISA TOMODA, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, YUSUKE HARAGUCHI, TOSHIKI KOGA, KENICHI HARADA, KENTARO KUROIWA, NAOHIRO FUJIMOTO, MOTONOBU NAKAMURA and Uro-Oncology Group in Kyushu (UROKYU)

Anticancer Research April 2024, 44 (4) 1675-1681; DOI: https://doi.org/10.21873/anticanres.16966
You have access
Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study
NOBUKI FURUBAYASHI, AKINORI MINATO, TOSHIHISA TOMODA, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, YUSUKE HARAGUCHI, TOSHIKI KOGA, KENTARO KUROIWA, NAOHIRO FUJIMOTO and MOTONOBU NAKAMURA

Anticancer Research December 2023, 43 (12) 5689-5698; DOI: https://doi.org/10.21873/anticanres.16774
You have access
Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study
NOBUKI FURUBAYASHI, AKINORI MINATO, TAKAHITO NEGISHI, NAOTAKA SAKAMOTO, YOOHYUN SONG, YOSHIFUMI HORI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, MIRII HARADA, SHINGO TAMURA, HIROKI KOBAYASHI, KAEDE MORIHARA, KENTARO KUROIWA, NARIHITO SEKI, NAOHIRO FUJIMOTO and MOTONOBU NAKAMURA

Anticancer Research October 2023, 43 (10) 4701-4708; DOI: https://doi.org/10.21873/anticanres.16666
Open Access
Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World
AKINORI MINATO, RIEKO KIMURO, DAICHI OHNO, KENTAROU TANIGAWA, KEISUKE KURETAKE, TAKUO MATSUKAWA, TOMOHISA TAKABA, KAZUMASA JOJIMA, MIRII HARADA, KATSUYOSHI HIGASHIJIMA, YUJIRO NAGATA, IKKO TOMISAKI, KENICHI HARADA, NAOHIRO FUJIMOTO and HIROSHI MIYAMOTO

Anticancer Research September 2023, 43 (9) 4055-4060; DOI: https://doi.org/10.21873/anticanres.16594
You have access
Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma
TAKESHI SANO, RIHITO AIZAWA, KATSUHIRO ITO, KIYONAO NAKAMURA, TAKASHI OGATA, MASASHI TAKEDA, AKIHIRO HAMADA, TAKASHI MATSUOKA, JIN KONO, YUKI KITA, KIMIHIKO MASUI, TAKAYUKI GOTO, ATSURO SAWADA, SHUSUKE AKAMATSU, OSAMU OGAWA, TAKASHI MIZOWAKI and TAKASHI KOBAYASHI

Anticancer Research May 2023, 43 (5) 2119-2126; DOI: https://doi.org/10.21873/anticanres.16373
Open Access
Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder
JETON LUZHA, NORBERT NASS, PIOTR CZAPIEWSKI, NICOLAS SCHROEDER, THOMAS KALINSKI, MARTIN SCHOSTAK, CHRISTOPH SCHATZ, BURKHARD JANDRIG and JOHANNES HAYBAECK

Anticancer Research April 2023, 43 (4) 1437-1448; DOI: https://doi.org/10.21873/anticanres.16292
You have access
Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells
SAN-YUAN CHEN, CHUN-NUN CHAO, HSIN-YI HUANG, PEI-WEN ZHAO and CHIUNG-YAO FANG

Anticancer Research March 2023, 43 (3) 1175-1184; DOI: https://doi.org/10.21873/anticanres.16263
You have access
First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU and CHENG-KUANG YANG

Anticancer Research March 2023, 43 (3) 1331-1339; DOI: https://doi.org/10.21873/anticanres.16281
You have access
Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
IKKO TOMISAKI, MIRII HARADA, SHIGERU SAKANO, MICHIKAZU TERADO, RYOICHI HAMASUNA, SHUJI HARADA, HIROOMI MATSUMOTO, SOICHIRO AKASAKA, YUJIRO NAGATA, AKINORI MINATO, KEN-ICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research January 2023, 43 (1) 269-274; DOI: https://doi.org/10.21873/anticanres.16159
You have access
Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer
SATOSHI INOUE, NAOTO SASSA, HIDEJI KAWANISHI, YURI YUGUCHI, TOMOHIDE SUZUKI, JUN NAGAYAMA, HIROTAKA MATSUI, YUDAI MIYATA, YUYA SOEDA, KOSUKE TOCHIGI, YUSHI YAMAUCHI, MOTOHIRO MAEDA, IKUO KOBAYASHI, RYOHEI HATTORI, YOSHIHISA MATSUKAWA and MASASHI KATO

Anticancer Research July 2022, 42 (7) 3627-3636; DOI: https://doi.org/10.21873/anticanres.15851

Main menu

User menu

Search

urothelial carcinoma

Pages